Details:

Personal Author:
Levine, Orin S. ; Schwartz, Benjamin ; Van Beneden, Chris A. ; Whitney, Cynthia G.
Levine, Orin S. ; Schwartz, Benjamin ; Van Beneden, Chris A. ; Whitney, Cynthia G. Less -
Corporate Authors:
United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; National Center for Infectious Diseases (U.S.). Division of Bacterial and Mycotic Diseases. ; National Immunization Program (Centers for Disease Control and Prevention). Division of Epidemiology and Surveillance.
United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; National Center for Infectious Diseases (U.S.). Division of Bacterial and Mycotic Diseases. ; National Immunization Program (Centers for Disease Control and Prevention). Division of Epidemiology and Surveillance. Less -
Description:
In February 2000, a 7-valent pneumococcal polysaccharide-protein conjugate vaccine (Prevnar, marketed by Wyeth Lederle Vaccines) was licensed for use among infants and young children. CDC's Advisory Committee on Immunization Practices (ACIP) recommends that the vaccine be used for all children aged 2-23 months and for children aged 24-59 months who are at increased risk for pneumococcal disease (e.g., children with sickle cell disease, human immunodeficiency virus infection, and other immunocompromising or chronic medical conditions). ACIP also recommends that the vaccine be considered for all other children aged 24-59 months, with priority given to a) children aged 24-35 months, b) children who are of Alaska Native, American Indian, and African-American descent, and c) children who attend group day care centers. This report includes ACIP's recommended vaccination schedule for infants at ages 2, 4, 6, and 12-15 months. This report also includes a pneumococcal vaccination schedule for infants and young children who are beginning their vaccination series at an older age and for those who missed doses. In addition, this report updates earlier recommendations for use of 23-valent pneumococcal polysaccharide vaccine among children aged > or =2 years. Among children aged 24-59 months for whom polysaccharide vaccine is already recommended, ACIP recommends vaccination with the new conjugate vaccine followed, > or =2 months later, by 23-valent polysaccharide vaccine. Conjugate vaccine has not been studied sufficiently among older children or adults to make recommendations for its use among persons aged > or =5 years. Persons aged > or =5 years who are at increased risk for serious pneumococcal disease should continue to receive 23-valent polysaccharide vaccine in accordance with previous ACIP recommendations.
Content Notes:
The following CDC staff members prepared this report: Chris A. Van Beneden, Cynthia G. Whitney, Orin S. Levine, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases; Benjamin Schwartz, Division of Epidemiology and Surveillance, National Immunization Program; in collaboration with the Advisory Committee on Immunization Practices Working Group on Pneumococcal Conjugate Vaccines.

Includes bibliographical references.


Subject:
[+]
Adult
Antibodies, Bacterial
Bacterial Vaccines
Child
Child, Preschool
Cost-Benefit Analysis
Drug Resistance, Microbial
Infant
Meningococcal Vaccines
Pneumococcal Infections
Pneumococcal Vaccines
Risk Factors
Streptococcus Pneumoniae
Vaccination
Vaccines, Conjugate

Series:
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 49, no. RR-9 PMID:11055835:MODS 11055835
Document Type:
Journal Issue
Place as Subject:
United States
Collection(s):
Advisory Committee on Immunization Practices (ACIP)
Stephen B. Thacker CDC Library collection
Main Document Checksum:
[+]
urn:sha256:0c154d5f1f564d29d2c099a7d4c2ffa01b146d1c02ebb1957006205028ae5f4e
File Type:

Supporting Files

• No Additional Files

More +